Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laodianhuang queen bee pupa freeze-dried tablets is a traditional Chinese medicine (TCM) or nutraceutical product derived from the freeze-dried larvae and pupae of queen bees. It is primarily utilized for its purported benefits in regulating the endocrine system, improving sleep quality, and addressing symptoms associated with female aging. The product is currently being evaluated in clinical trials led by Dongzhimen Hospital, affiliated with the Beijing University of Chinese Medicine, specifically for its efficacy in treating insomnia and sleep disorders in women. It is characterized by a high concentration of proteins, amino acids, and bioactive substances inherent to queen bee development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Laodianhuang queen bee pupa freeze-dried tablets.